WuXi Biologics is pleased to announce its audited annual results for the year ended December 31, 2021. Our CRDMO business model and a focus on innovation, quality, expertise, project execution and delivery timelines, along with our “Follow and Win the Molecule” strategies helped us capture opportunities, increase our market share, and achieve new revenue and profitability records in 2021.